| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 60 | 2023 | 5171 | 4.070 |
Why?
|
| Lung Neoplasms | 79 | 2023 | 13019 | 3.540 |
Why?
|
| Quinazolines | 25 | 2012 | 1355 | 2.620 |
Why?
|
| Protein Kinase Inhibitors | 35 | 2023 | 5522 | 2.350 |
Why?
|
| Receptor, erbB-3 | 7 | 2021 | 142 | 2.050 |
Why?
|
| Exons | 11 | 2022 | 2431 | 1.860 |
Why?
|
| Antineoplastic Agents | 39 | 2022 | 13655 | 1.660 |
Why?
|
| Mesothelioma | 13 | 2008 | 818 | 1.430 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2021 | 5163 | 1.430 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 14 | 2023 | 1683 | 1.330 |
Why?
|
| Pleural Neoplasms | 9 | 2008 | 607 | 1.230 |
Why?
|
| Aniline Compounds | 4 | 2023 | 983 | 1.220 |
Why?
|
| Mutation | 41 | 2023 | 29717 | 1.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 8 | 2020 | 578 | 1.080 |
Why?
|
| Receptor, erbB-2 | 7 | 2022 | 2410 | 1.060 |
Why?
|
| Genes, ras | 7 | 2021 | 691 | 0.930 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2020 | 11472 | 0.860 |
Why?
|
| Mutagenesis, Insertional | 3 | 2022 | 655 | 0.810 |
Why?
|
| Gene Amplification | 6 | 2020 | 1062 | 0.800 |
Why?
|
| Cell Line, Tumor | 37 | 2023 | 16665 | 0.780 |
Why?
|
| Benzeneacetamides | 1 | 2019 | 39 | 0.690 |
Why?
|
| Guanine | 5 | 2008 | 274 | 0.650 |
Why?
|
| Acrylamides | 2 | 2020 | 252 | 0.650 |
Why?
|
| Glutamates | 5 | 2008 | 398 | 0.640 |
Why?
|
| Camptothecin | 1 | 2021 | 572 | 0.630 |
Why?
|
| Indoles | 3 | 2021 | 1834 | 0.620 |
Why?
|
| Oncogenes | 3 | 2021 | 1263 | 0.590 |
Why?
|
| Pyrimidines | 8 | 2023 | 2933 | 0.550 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 731 | 0.540 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2021 | 3585 | 0.520 |
Why?
|
| Adenocarcinoma | 9 | 2016 | 6347 | 0.520 |
Why?
|
| Immunoconjugates | 1 | 2021 | 897 | 0.480 |
Why?
|
| Thiazoles | 3 | 2019 | 1484 | 0.480 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2020 | 3557 | 0.450 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2020 | 4553 | 0.450 |
Why?
|
| High-Throughput Screening Assays | 2 | 2018 | 944 | 0.450 |
Why?
|
| Maximum Tolerated Dose | 6 | 2021 | 891 | 0.400 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 1820 | 0.390 |
Why?
|
| Enzyme Inhibitors | 7 | 2023 | 3800 | 0.390 |
Why?
|
| ras Proteins | 5 | 2020 | 1060 | 0.380 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2007 | 91 | 0.360 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2012 | 337 | 0.350 |
Why?
|
| Carboplatin | 2 | 2012 | 799 | 0.350 |
Why?
|
| Taxoids | 1 | 2012 | 665 | 0.340 |
Why?
|
| Humans | 122 | 2023 | 742088 | 0.330 |
Why?
|
| MAP Kinase Signaling System | 6 | 2020 | 1525 | 0.330 |
Why?
|
| Mutation, Missense | 5 | 2023 | 2556 | 0.330 |
Why?
|
| Heptanoic Acids | 1 | 2011 | 343 | 0.330 |
Why?
|
| Cisplatin | 5 | 2006 | 1637 | 0.320 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 2007 | 17 | 0.320 |
Why?
|
| Benzimidazoles | 2 | 2013 | 848 | 0.320 |
Why?
|
| Sulfones | 3 | 2018 | 437 | 0.320 |
Why?
|
| Apoptosis | 11 | 2021 | 9715 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2020 | 220 | 0.300 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2007 | 96 | 0.290 |
Why?
|
| Morpholines | 2 | 2007 | 561 | 0.290 |
Why?
|
| Mice | 24 | 2021 | 81045 | 0.290 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2020 | 1581 | 0.280 |
Why?
|
| Pyrazoles | 4 | 2020 | 1970 | 0.280 |
Why?
|
| Disease-Free Survival | 8 | 2021 | 6891 | 0.280 |
Why?
|
| Quinolines | 4 | 2020 | 719 | 0.280 |
Why?
|
| Phosphatidylinositol 3-Kinases | 8 | 2018 | 2938 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2020 | 8425 | 0.280 |
Why?
|
| Receptors, Growth Factor | 1 | 2007 | 334 | 0.270 |
Why?
|
| Quinazolinones | 1 | 2007 | 221 | 0.270 |
Why?
|
| DNA, Neoplasm | 7 | 2018 | 1758 | 0.270 |
Why?
|
| Pyridazines | 2 | 2020 | 201 | 0.270 |
Why?
|
| Deoxyribonuclease I | 1 | 2006 | 228 | 0.260 |
Why?
|
| Signal Transduction | 15 | 2019 | 23387 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 10 | 2013 | 2502 | 0.250 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2018 | 2638 | 0.250 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2012 | 1284 | 0.240 |
Why?
|
| Animals | 31 | 2021 | 168561 | 0.240 |
Why?
|
| Treatment Outcome | 24 | 2021 | 62966 | 0.240 |
Why?
|
| Benzamides | 5 | 2020 | 1378 | 0.230 |
Why?
|
| DNA Mutational Analysis | 8 | 2019 | 4187 | 0.230 |
Why?
|
| Aged, 80 and over | 24 | 2021 | 57683 | 0.230 |
Why?
|
| Phosphorylation | 11 | 2012 | 8436 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2021 | 10943 | 0.220 |
Why?
|
| Survival Analysis | 12 | 2008 | 10248 | 0.220 |
Why?
|
| raf Kinases | 2 | 2020 | 122 | 0.220 |
Why?
|
| Aged | 41 | 2021 | 162944 | 0.220 |
Why?
|
| Loss of Heterozygosity | 2 | 2004 | 678 | 0.210 |
Why?
|
| Carcinoid Tumor | 1 | 2004 | 235 | 0.210 |
Why?
|
| Middle Aged | 44 | 2021 | 213127 | 0.210 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 18006 | 0.210 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2020 | 2455 | 0.200 |
Why?
|
| Cell Proliferation | 10 | 2020 | 10472 | 0.200 |
Why?
|
| Female | 52 | 2023 | 379592 | 0.200 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2013 | 1659 | 0.200 |
Why?
|
| Imidazoles | 2 | 2020 | 1205 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 6313 | 0.190 |
Why?
|
| Food-Drug Interactions | 1 | 2020 | 27 | 0.190 |
Why?
|
| NIH 3T3 Cells | 3 | 2019 | 677 | 0.190 |
Why?
|
| ras-GRF1 | 1 | 2020 | 26 | 0.190 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2018 | 2028 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 164 | 0.180 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2021 | 187 | 0.180 |
Why?
|
| Amino Acid Substitution | 4 | 2017 | 1792 | 0.180 |
Why?
|
| Mice, Transgenic | 6 | 2019 | 9735 | 0.180 |
Why?
|
| Drug Synergism | 4 | 2019 | 1791 | 0.180 |
Why?
|
| Acetonitriles | 1 | 2019 | 52 | 0.180 |
Why?
|
| Male | 48 | 2021 | 349538 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2011 | 2940 | 0.170 |
Why?
|
| Receptors, CXCR | 1 | 2019 | 52 | 0.170 |
Why?
|
| Peritoneal Neoplasms | 1 | 2005 | 663 | 0.170 |
Why?
|
| Adult | 37 | 2021 | 213712 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 6 | 2017 | 9274 | 0.170 |
Why?
|
| Pyridines | 4 | 2020 | 2818 | 0.170 |
Why?
|
| Luciferases, Firefly | 1 | 2018 | 46 | 0.160 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2019 | 185 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2007 | 2915 | 0.160 |
Why?
|
| Genomics | 8 | 2023 | 5692 | 0.160 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 4839 | 0.160 |
Why?
|
| Mice, Inbred NOD | 2 | 2020 | 1875 | 0.160 |
Why?
|
| Spheroids, Cellular | 1 | 2020 | 351 | 0.160 |
Why?
|
| Allosteric Regulation | 1 | 2019 | 408 | 0.150 |
Why?
|
| Mice, SCID | 2 | 2020 | 2715 | 0.150 |
Why?
|
| Pyrrolidines | 1 | 2019 | 342 | 0.150 |
Why?
|
| Meningeal Neoplasms | 1 | 2006 | 1241 | 0.150 |
Why?
|
| Disease Progression | 9 | 2017 | 13256 | 0.150 |
Why?
|
| Epidermal Growth Factor | 3 | 2005 | 709 | 0.150 |
Why?
|
| Personality | 1 | 2000 | 548 | 0.140 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 2271 | 0.140 |
Why?
|
| Drug Administration Schedule | 5 | 2008 | 4929 | 0.140 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2021 | 384 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2007 | 3920 | 0.140 |
Why?
|
| Janus Kinase 2 | 2 | 2018 | 527 | 0.140 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 1940 | 0.140 |
Why?
|
| Alleles | 2 | 2006 | 6931 | 0.130 |
Why?
|
| Smoking | 2 | 2012 | 8969 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 567 | 0.130 |
Why?
|
| Molecular Conformation | 1 | 2017 | 563 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 516 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2023 | 2107 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2007 | 480 | 0.130 |
Why?
|
| Killer Cells, Natural | 2 | 2022 | 2133 | 0.130 |
Why?
|
| Janus Kinase 3 | 1 | 2015 | 78 | 0.130 |
Why?
|
| Codon | 1 | 2017 | 611 | 0.130 |
Why?
|
| Membrane Proteins | 3 | 2022 | 7873 | 0.130 |
Why?
|
| Neoplasms | 9 | 2020 | 21596 | 0.130 |
Why?
|
| Piperazines | 2 | 2019 | 2488 | 0.130 |
Why?
|
| Pyrrolidinones | 1 | 2015 | 117 | 0.130 |
Why?
|
| Coculture Techniques | 1 | 2018 | 1341 | 0.120 |
Why?
|
| Iodine Radioisotopes | 1 | 2018 | 1030 | 0.120 |
Why?
|
| Gene Dosage | 3 | 2010 | 1251 | 0.120 |
Why?
|
| Prognosis | 10 | 2023 | 29010 | 0.120 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 11001 | 0.120 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2014 | 105 | 0.120 |
Why?
|
| Cell Cycle | 4 | 2013 | 2964 | 0.120 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 1670 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2016 | 15494 | 0.120 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 808 | 0.120 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 325 | 0.120 |
Why?
|
| Nucleoside-Phosphate Kinase | 1 | 2013 | 23 | 0.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 713 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1255 | 0.120 |
Why?
|
| Clinical Trials as Topic | 6 | 2016 | 7901 | 0.110 |
Why?
|
| Immunity | 1 | 2019 | 1011 | 0.110 |
Why?
|
| Cell Survival | 3 | 2019 | 5872 | 0.110 |
Why?
|
| Naphthyridines | 1 | 2013 | 118 | 0.110 |
Why?
|
| Internal-External Control | 3 | 2003 | 363 | 0.110 |
Why?
|
| Carcinoma, Small Cell | 2 | 2005 | 420 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 6 | 2021 | 2723 | 0.100 |
Why?
|
| ran GTP-Binding Protein | 1 | 2011 | 54 | 0.100 |
Why?
|
| RNA Interference | 4 | 2013 | 2890 | 0.100 |
Why?
|
| Mice, Nude | 4 | 2019 | 3689 | 0.100 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 500 | 0.100 |
Why?
|
| Receptors, Mitogen | 1 | 2011 | 62 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 2842 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 526 | 0.100 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 749 | 0.100 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 712 | 0.100 |
Why?
|
| Tumor Escape | 1 | 2013 | 349 | 0.090 |
Why?
|
| src-Family Kinases | 2 | 2011 | 551 | 0.090 |
Why?
|
| Point Mutation | 2 | 2006 | 1624 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 3 | 2006 | 3847 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2007 | 11470 | 0.090 |
Why?
|
| Placebos | 2 | 2012 | 1677 | 0.090 |
Why?
|
| Transfection | 3 | 2006 | 5892 | 0.090 |
Why?
|
| Enzyme Activation | 3 | 2015 | 3701 | 0.090 |
Why?
|
| Sequence Analysis | 1 | 2010 | 256 | 0.090 |
Why?
|
| Butadienes | 2 | 2007 | 110 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 6754 | 0.080 |
Why?
|
| Genome, Human | 3 | 2016 | 4420 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2020 | 319 | 0.080 |
Why?
|
| Genotype | 4 | 2018 | 12946 | 0.080 |
Why?
|
| Combined Modality Therapy | 6 | 2007 | 8621 | 0.080 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2013 | 608 | 0.080 |
Why?
|
| Hematopoiesis | 1 | 2018 | 2066 | 0.080 |
Why?
|
| Models, Molecular | 2 | 2017 | 5454 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2016 | 1983 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2012 | 625 | 0.080 |
Why?
|
| Genes, p53 | 2 | 2007 | 755 | 0.080 |
Why?
|
| Folic Acid Antagonists | 1 | 2008 | 82 | 0.080 |
Why?
|
| Mutant Proteins | 1 | 2010 | 500 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2010 | 379 | 0.080 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2010 | 433 | 0.080 |
Why?
|
| Cell Division | 2 | 2007 | 4564 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2014 | 1723 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2948 | 0.080 |
Why?
|
| Treatment Failure | 4 | 2007 | 2615 | 0.070 |
Why?
|
| Protein Binding | 2 | 2017 | 9387 | 0.070 |
Why?
|
| CHO Cells | 2 | 2007 | 1407 | 0.070 |
Why?
|
| Genes, p16 | 1 | 2007 | 157 | 0.070 |
Why?
|
| Mosaicism | 1 | 2010 | 440 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 9185 | 0.070 |
Why?
|
| Bronchial Neoplasms | 1 | 2007 | 112 | 0.070 |
Why?
|
| Gene Expression | 2 | 2017 | 7790 | 0.070 |
Why?
|
| Chromosome Mapping | 2 | 2006 | 4742 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2013 | 2024 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 4801 | 0.070 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 11363 | 0.070 |
Why?
|
| Stress, Psychological | 2 | 2003 | 4229 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 1574 | 0.070 |
Why?
|
| Cricetinae | 2 | 2007 | 2471 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2010 | 774 | 0.070 |
Why?
|
| Liver Failure, Acute | 1 | 2007 | 165 | 0.070 |
Why?
|
| Doxycycline | 1 | 2007 | 326 | 0.070 |
Why?
|
| Radiation Pneumonitis | 1 | 2006 | 104 | 0.070 |
Why?
|
| Sirolimus | 3 | 2012 | 1562 | 0.070 |
Why?
|
| Genes, Neoplasm | 1 | 2007 | 376 | 0.070 |
Why?
|
| Chromones | 1 | 2005 | 154 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2023 | 5851 | 0.070 |
Why?
|
| Survival | 1 | 2005 | 162 | 0.070 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2005 | 135 | 0.060 |
Why?
|
| Cricetulus | 1 | 2007 | 817 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2023 | 1434 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 4438 | 0.060 |
Why?
|
| Paraffin Embedding | 1 | 2006 | 299 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 459 | 0.060 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 400 | 0.060 |
Why?
|
| Thrombocythemia, Essential | 1 | 2006 | 103 | 0.060 |
Why?
|
| Pleura | 1 | 2006 | 235 | 0.060 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2018 | 890 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2006 | 1526 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 2712 | 0.060 |
Why?
|
| Cell Shape | 1 | 2005 | 375 | 0.060 |
Why?
|
| Interleukin-3 | 1 | 2005 | 441 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 2274 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 2542 | 0.060 |
Why?
|
| Polycythemia Vera | 1 | 2006 | 163 | 0.060 |
Why?
|
| Formaldehyde | 1 | 2006 | 353 | 0.060 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2005 | 270 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 640 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 6171 | 0.060 |
Why?
|
| Nitriles | 2 | 2007 | 952 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2008 | 824 | 0.060 |
Why?
|
| Medical Oncology | 3 | 2011 | 2235 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 3444 | 0.060 |
Why?
|
| Pneumonectomy | 2 | 2007 | 1093 | 0.060 |
Why?
|
| Finland | 1 | 2005 | 602 | 0.060 |
Why?
|
| Eukaryotic Initiation Factor-4F | 1 | 2023 | 41 | 0.060 |
Why?
|
| Genes, erbB-1 | 1 | 2004 | 161 | 0.060 |
Why?
|
| Administration, Oral | 3 | 2007 | 3913 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 39004 | 0.060 |
Why?
|
| Exanthema | 1 | 2007 | 488 | 0.050 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2023 | 131 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 21821 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2007 | 1097 | 0.050 |
Why?
|
| Hyperthermia, Induced | 1 | 2006 | 401 | 0.050 |
Why?
|
| Survival Rate | 2 | 2007 | 12773 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 1374 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2007 | 4322 | 0.050 |
Why?
|
| Models, Biological | 1 | 2018 | 9581 | 0.050 |
Why?
|
| Tuberous Sclerosis | 1 | 2010 | 1029 | 0.050 |
Why?
|
| Sensitivity and Specificity | 4 | 2019 | 14720 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2004 | 800 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 692 | 0.050 |
Why?
|
| Prospective Studies | 7 | 2019 | 53187 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 20086 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1640 | 0.050 |
Why?
|
| Depression | 1 | 2000 | 7733 | 0.050 |
Why?
|
| Remission Induction | 1 | 2006 | 2384 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2007 | 5180 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2016 | 3306 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 9410 | 0.050 |
Why?
|
| Diarrhea | 1 | 2007 | 1343 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 364 | 0.050 |
Why?
|
| Carcinoma | 1 | 2011 | 2374 | 0.040 |
Why?
|
| Tumor Microenvironment | 3 | 2019 | 3564 | 0.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2006 | 806 | 0.040 |
Why?
|
| Terminal Care | 1 | 2011 | 1688 | 0.040 |
Why?
|
| Receptor, trkA | 1 | 2020 | 164 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2017 | 1905 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2011 | 1769 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2003 | 783 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2005 | 1811 | 0.040 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 1274 | 0.040 |
Why?
|
| Cytokines | 1 | 2013 | 7317 | 0.040 |
Why?
|
| Communication | 2 | 2003 | 3728 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2020 | 4200 | 0.040 |
Why?
|
| Databases, Genetic | 2 | 2016 | 1780 | 0.040 |
Why?
|
| Base Sequence | 2 | 2006 | 12797 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 2633 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2013 | 1655 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2023 | 861 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2004 | 2633 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2019 | 288 | 0.040 |
Why?
|
| Antibodies | 1 | 2005 | 2459 | 0.040 |
Why?
|
| Confidence Intervals | 3 | 2007 | 2970 | 0.040 |
Why?
|
| Patient Selection | 2 | 2007 | 4214 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2004 | 2713 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2013 | 10163 | 0.040 |
Why?
|
| Quality of Life | 2 | 2011 | 12730 | 0.040 |
Why?
|
| National Human Genome Research Institute (U.S.) | 1 | 2016 | 23 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2217 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 2335 | 0.040 |
Why?
|
| Software | 2 | 2016 | 4434 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2001 | 839 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 6483 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2007 | 15056 | 0.030 |
Why?
|
| Young Adult | 5 | 2021 | 56350 | 0.030 |
Why?
|
| Multiprotein Complexes | 2 | 2012 | 1119 | 0.030 |
Why?
|
| Genome | 1 | 2004 | 1803 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 9639 | 0.030 |
Why?
|
| Germ-Line Mutation | 2 | 2016 | 1786 | 0.030 |
Why?
|
| Population Groups | 1 | 2016 | 208 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2016 | 261 | 0.030 |
Why?
|
| Cell Movement | 2 | 2005 | 5212 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1866 | 0.030 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1995 | 109 | 0.030 |
Why?
|
| Retrospective Studies | 6 | 2018 | 77098 | 0.030 |
Why?
|
| Lung | 2 | 2019 | 9826 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2006 | 23320 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6534 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2016 | 981 | 0.030 |
Why?
|
| Thymine Nucleotides | 1 | 2013 | 63 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1038 | 0.030 |
Why?
|
| Algorithms | 1 | 2014 | 13853 | 0.030 |
Why?
|
| Forecasting | 1 | 2003 | 2948 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 732 | 0.030 |
Why?
|
| Okadaic Acid | 1 | 2012 | 67 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2016 | 648 | 0.030 |
Why?
|
| Depressive Disorder | 2 | 1995 | 3748 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 1179 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2013 | 1159 | 0.020 |
Why?
|
| Furans | 1 | 2012 | 194 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 3478 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2020 | 1932 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 1837 | 0.020 |
Why?
|
| Fluoxetine | 1 | 1995 | 749 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2011 | 20774 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2012 | 215 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 434 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5062 | 0.020 |
Why?
|
| Health Status | 1 | 2004 | 4030 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2011 | 3471 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2012 | 320 | 0.020 |
Why?
|
| Social Support | 1 | 2000 | 2117 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2012 | 337 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 6382 | 0.020 |
Why?
|
| Morphine | 1 | 1995 | 657 | 0.020 |
Why?
|
| International Cooperation | 1 | 2017 | 1421 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 2524 | 0.020 |
Why?
|
| Sex Factors | 1 | 2004 | 10392 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2011 | 438 | 0.020 |
Why?
|
| Osteopontin | 1 | 2011 | 296 | 0.020 |
Why?
|
| Western World | 1 | 2009 | 27 | 0.020 |
Why?
|
| Age Factors | 1 | 2007 | 18355 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2012 | 479 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2000 | 2575 | 0.020 |
Why?
|
| Threonine | 1 | 2010 | 279 | 0.020 |
Why?
|
| Research Design | 1 | 2005 | 5979 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 3839 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2009 | 295 | 0.020 |
Why?
|
| Pedigree | 1 | 2016 | 4646 | 0.020 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 6259 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 411 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 2885 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2001 | 3215 | 0.020 |
Why?
|
| Anthracenes | 1 | 2007 | 84 | 0.020 |
Why?
|
| Cell Death | 1 | 2013 | 1695 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 8297 | 0.020 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2007 | 110 | 0.020 |
Why?
|
| Proteins | 2 | 2012 | 6096 | 0.020 |
Why?
|
| Multigene Family | 1 | 2010 | 1102 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 1158 | 0.020 |
Why?
|
| Tablets | 1 | 2006 | 147 | 0.020 |
Why?
|
| DNA Replication | 1 | 2013 | 1397 | 0.020 |
Why?
|
| Cell Line | 2 | 2013 | 15994 | 0.020 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2005 | 46 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2007 | 643 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2005 | 118 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 1144 | 0.020 |
Why?
|
| Italy | 1 | 2007 | 828 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2007 | 452 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1995 | 2051 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2010 | 1907 | 0.020 |
Why?
|
| Time Factors | 2 | 2005 | 40054 | 0.020 |
Why?
|
| Drug Approval | 1 | 2011 | 740 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 1995 | 2281 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2011 | 1520 | 0.020 |
Why?
|
| Kinetics | 1 | 2013 | 6474 | 0.020 |
Why?
|
| Autophagy | 1 | 2013 | 1301 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 1801 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 905 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 1995 | 1638 | 0.020 |
Why?
|
| Physicians | 1 | 2003 | 4554 | 0.020 |
Why?
|
| Metabolomics | 1 | 2013 | 1467 | 0.020 |
Why?
|
| Hospice Care | 1 | 2011 | 671 | 0.020 |
Why?
|
| Endonucleases | 1 | 2007 | 381 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2007 | 697 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2009 | 933 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 1989 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4440 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2011 | 1166 | 0.010 |
Why?
|
| Radiography | 1 | 2015 | 7010 | 0.010 |
Why?
|
| Educational Status | 1 | 2011 | 2533 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2011 | 2751 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 8829 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 3612 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 187 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2023 | 12164 | 0.010 |
Why?
|
| DNA Damage | 1 | 2013 | 2423 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2012 | 4211 | 0.010 |
Why?
|
| Research | 1 | 2011 | 1999 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2005 | 322 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 1995 | 2838 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2013 | 3493 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 839 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3691 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 2203 | 0.010 |
Why?
|
| United States | 4 | 2016 | 69693 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 5519 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 1950 | 0.010 |
Why?
|
| Role Playing | 1 | 2001 | 24 | 0.010 |
Why?
|
| Health Care Reform | 1 | 2011 | 1261 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 18112 | 0.010 |
Why?
|
| DNA Primers | 1 | 2006 | 2892 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2005 | 535 | 0.010 |
Why?
|
| Computational Biology | 1 | 2014 | 3518 | 0.010 |
Why?
|
| Drug Discovery | 1 | 2010 | 1057 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2005 | 670 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2004 | 936 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2005 | 874 | 0.010 |
Why?
|
| Registries | 1 | 2017 | 8077 | 0.010 |
Why?
|
| Massachusetts | 1 | 2014 | 8662 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2007 | 2876 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2005 | 1400 | 0.010 |
Why?
|
| Japan | 1 | 2004 | 1360 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1995 | 6078 | 0.010 |
Why?
|
| ROC Curve | 1 | 2007 | 3528 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4751 | 0.010 |
Why?
|
| Homozygote | 1 | 2004 | 1777 | 0.010 |
Why?
|
| Health Policy | 1 | 2011 | 2657 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2007 | 2440 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2007 | 6365 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 40450 | 0.010 |
Why?
|
| Feedback | 1 | 2001 | 793 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2005 | 1707 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 7770 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 3070 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2006 | 1199 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 7721 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 3502 | 0.010 |
Why?
|
| Phenotype | 2 | 2010 | 16331 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 3151 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2007 | 3020 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2011 | 4414 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2004 | 4013 | 0.010 |
Why?
|
| Child | 2 | 2016 | 77478 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 2536 | 0.010 |
Why?
|
| Moclobemide | 1 | 1995 | 4 | 0.010 |
Why?
|
| Adolescent | 2 | 2021 | 85649 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 5133 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2005 | 2721 | 0.010 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 1995 | 187 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2005 | 3465 | 0.010 |
Why?
|
| DNA | 1 | 2007 | 7289 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 13814 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1995 | 1026 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 4249 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 9941 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12242 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 3391 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 15108 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 17400 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 35342 | 0.000 |
Why?
|
| Psychometrics | 1 | 1995 | 2999 | 0.000 |
Why?
|
| Pain Measurement | 1 | 1995 | 3418 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1995 | 4664 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1995 | 12017 | 0.000 |
Why?
|
| Anxiety | 1 | 1995 | 4279 | 0.000 |
Why?
|